PI(16:2(9Z,12Z)/22:3(10Z,13Z,16Z))

Term ID

CHEBI:88559

Synonyms

1-(9Z,12Z-Hexadecadienoate
1-(9Z,12Z-Hexadecadienoate)-2-(10Z,13Z,16Z-docosatrienoyl)-sn-glycero-3-phospho-(1'-myo-inositol)
1-(9Z,12Z-Hexadecadienoate)-2-(10Z,13Z,16Z-docosatrienoyl)-sn-glycero-3-phosphoinositol
1-(9Z,12Z-Hexadecadienoic acid
[(2R)-2-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyloxy]-3-[(9Z,12Z)-hexadeca-9,12-dienoyloxy]propoxy]({[(1s,3R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid
Phosphatidylinositol(16:2/22:3)
Phosphatidylinositol(16:2n4/22:3n6)
Phosphatidylinositol(16:2w4/22:3w6)
Phosphatidylinositol(38:5)
PI(16:2/22:3)
PI(16:2n4/22:3n6)
PI(16:2w4/22:3w6)
PI(38:5)
PIno(16:2/22:3)
PIno(16:2n4/22:3n6)
PIno(16:2w4/22:3w6)
PIno(38:5)

(all 17)

Definition

References

(all 4)

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from PI(16:2(9Z,12Z)/22:3(10Z,13Z,16Z))

Phenotype where environments contain PI(16:2(9Z,12Z)/22:3(10Z,13Z,16Z))

Phenotype modified by environments containing PI(16:2(9Z,12Z)/22:3(10Z,13Z,16Z))

Phenotype affecting PI(16:2(9Z,12Z)/22:3(10Z,13Z,16Z))

Human Disease Model